Flexion Therapeutics, Inc. (FLXN): What are the Technicals Saying?


Increasing profits are the best indication that a company can pay dividends and that the share price will trend upward.

Other analysts also recently issued reports about the stock. BMO Capital Markets now has an outperform rating on the stock.

Flexion Therapeutics, Inc. (FLXN) has been given an average price target of $36.67 from analysts, according to data collected by Finviz. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold".

A number of other research analysts also recently issued reports on FLXN. In a transaction dated Jun. 05, 2017, the shares were bought at an average price of $17.23, giving away a sum of $86,150.

Shares of Flexion Therapeutics (NASDAQ:FLXN) traded down 5.6796% during midday trading on Monday, hitting $28.2301.

Donald Trump Mocks Jemele Hill After Suspension from ESPN
Hill had called the president "a white supremacist who has largely surrounded himself w/ other white supremacists". She clarified Monday she was not calling for an National Football League boycott.

A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. Considering that the stock daily volume of 8.73 million shares, this represents a pretty noteworthy trading in volume size. The stock closing price is now trading upward to its 50 day moving average with change of 25.35%, escalated to its 20 day moving average with figure of 20.00% and above its 200 day moving average with value 38.57%. In this case, shares are 77.28% higher from $15.93, the worst price in 52 weeks suffered on November 08, 2016, and are keeping their losses at 6.09% for the past six months.

Flexion Therapeutics (NASDAQ:FLXN) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.11). The average investment recommendation on a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell) is 1.70, which implies that analysts are generally bullish in their outlook for FLXN over the next year. The Flexion Therapeutics, Inc. has Relative Strength Index (RSI 14) of 73.34 along with Average True Range (ATR 14) of 1.65. "(FLXN) PT Raised to $37.00 at BMO Capital Markets" was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this article on another publication, it was copied illegally and republished in violation of U.S. and global copyright and trademark legislation. Gilder Gagnon Howe & Communications Limited Liability Company has invested 1.28% in Flexion Therapeutics Inc (NASDAQ:FLXN). The total value of its holdings decreased 0.0%. Following the acquisition, the insider now directly owns 5,000 shares of the company's stock, valued at $120,750. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Insiders ownership held at 0.30% in the company. Public Employees Retirement System of OH now owns 41,644 shares of the specialty pharmaceutical company's stock worth $842,000 after acquiring an additional 17,066 shares in the last quarter. Parametric Portfolio Associates LLC now owns 27,600 shares of the specialty pharmaceutical company's stock valued at $743,000 after purchasing an additional 12,181 shares during the last quarter.

ILLEGAL ACTIVITY WARNING: "Janney Montgomery Scott Boosts Flexion Therapeutics, Inc". Closing price generally refers to the last price at which a stock trades during a regular trading session.

03/23/2017 - Flexion Therapeutics Inc had its "outperform" rating reiterated by analysts at Wells Fargo. The value of the investment in FLXN decreased from $4,059,000 to $3,132,000 decreasing 22.8% since the last quarter. Swiss National Bank now owns 35,911 shares of the specialty pharmaceutical company's stock valued at $966,000 after purchasing an additional 4,200 shares during the last quarter. The stock grabbed 20 new institutional investments totaling 1,561,397 shares while 19 institutional investors sold out their entire positions totaling 1,134,925 shares. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.